Clinical trials: Breath Analysis
Chronic Liver Disease
Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation
The objectives of this study are: To evaluate the ability of the Methacetin Breath Test (MBT) to detect hepatic decompensation events To evaluate the relationship between liver Biopsy and clinical outcome and show that the MBT…
- Trial name
- NCT02084160
- Where
- 4 sites in United States, Israel
- Volunteers
- 579 people
- Sponsor
- Meridian Bioscience, Inc.
Acute Liver Failure
13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF
The ALFSG-MBT protocol is for a multicenter, open label, non-randomized study to determine the value of Breath Identification® (BreathID®) N-(4-Methoxy-13C-phenyl)acetamide (13C-Methacetin) Breath Test System in predicting the…
- Trial name
- ALFSG-MBT (NCT02786836)
- Testing
- 13C-Methacetin
- Where
- 11 sites in United States
- Volunteers
- 76 people
- Sponsor
- University of Texas Southwestern Medical Center
Helicobacter Pylori Infection
13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
Approximately 200 patients with suspected H.pylori will be tested with a 13C-Urea Breath Test (UBT) to ascertain H.pylori positive.
- Trial name
- NCT00825630
- Testing
- Lansoprazole (Lanton), Omeprezole (Losec), Pantoprazole(Controloc)
- Where
- Israel
- Volunteers
- 123 people
- Sponsor
- Meridian Bioscience, Inc.
Breast Cancer
Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer
RATIONALE: A breath test that measures enzymes may be effective in identifying women in whom tamoxifen may not be effective. PURPOSE: This clinical trial is studying a breath test to see how well it works in women receiving…
- Trial name
- NCT00873366
- Testing
- dextromethorphan hydrobromide, tamoxifen citrate, high performance liquid chromatography
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Mayo Clinic
Gastroparesis
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
GSK962040 is a novel small molecule motilin agonist. The Phase I studies (MOT107043 and MOT109681) demonstrated that single doses of GSK962040 up to 150 mg and repeat dosing of up to 125 mg/day for 14 days were well tolerated…
- Trial name
- NCT01262898
- Testing
- GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet)
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Patients With Compensated Liver Cirrhosis
Assessing Portal Hypertension With Methacetin Breath Test
This study will be used to train an algorithm using Methacetin breath test (MBT) measures and to select a cut-off to determine presence or absence of Clinically Significant Portal Hypertension (CSPH) as defined by Hepatic Venous…
- Trial name
- NCT02143778
- Testing
- Methacetin Breath Test
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 246 people
- Sponsor
- Meridian Bioscience, Inc.
Helicobacter Pylori Infection
Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection
The Exalenz Dual Mode BreathID® Hp System comprised of IDkit: Hp™ TWO and the Dual Mode BreathID® Hp test device will be used to perform a urea breath test in the initial diagnosis and post treatment monitoring of H.pylori…
- Trial name
- NCT02528721
- Testing
- Dual Mode BreathID Hp System
- Where
- 13 sites in United States, Israel
- Volunteers
- 282 people
- Sponsor
- Meridian Bioscience, Inc.
COPD Exacerbation
Molecular Breath Print of COPD Patients With Exacerbations Despite Triple Inhalational Therapy
Determination of specific molecular breath patterns by secondary electrospray ionization mass spectrometry (SESIHRMS) during and 8 weeks after a COPD exacerbation.
- Trial name
- TripleEX (NCT04638920)
- Testing
- No intervention
- Where
- Switzerland
- Volunteers
- 35 people
- Sponsor
- Malcolm Kohler
Pulmonary Embolism
Breath Analysis Technique to Diagnose Pulmonary Embolism
A pulmonary embolism (PE) is a blockage in one of the arteries of the lungs, and is usually caused by a traveling blood clot. The D-dimer blood test is currently used to diagnose PEs, but it is not always accurate for individuals…
- Trial name
- NCT00368836
- Testing
- BreathScreen PE
- Where
- United States
- Volunteers
- 475 people
- Sponsor
- Wake Forest University Health Sciences
Liver Diseases, Liver Cancer
Breath Analysis Based Disease Biomarkers
The purpose of the study is to develop a clinical test based on breath analysis that can be used for disease diagnosis or prognosis.
- Conditions
- Liver Diseases, Liver Cancer, COVID19
- Trial name
- NCT04341012
- Testing
- Collection of breath sample
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
NASH - Nonalcoholic Steatohepatitis
Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials
This is a companion study assessing the ¹³C-Methacetin Breath Test (MBT) in subjects participating in the Bristol Myers-Squibb (BMS) NCT03486899 and NCT03486912 referenced studies using study drug BMS-986036.
- Trial name
- NCT03611101
- Testing
- ¹³C-Methacetin Breath Test, BMS-986036, BreathID MCS device
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Meridian Bioscience, Inc.
Bronchiectasis
Assessment of an Exhaled Breath Test to Detect Bronchiectasis
To investigate whether the breath test is able to detect bronchiectasis using breathomics. This study was conducted with a prospective specimen collection, evaluator-blinded, case-controlled clinical study designed to evaluate…
- Trial name
- NCT05293314
- Testing
- An exhaled breath test
- Where
- China
- Volunteers
- 544 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Colorectal Cancer, Colorectal Polyps
The Colorectal Breath Analysis (COBRA) Study
This study aims to determine whether a breath test could be used for early detection of colorectal cancer and colorectal polyps.
- Conditions
- Colorectal Cancer, Colorectal Polyps, Colorectal Adenocarcinoma
- Trial name
- COBRA (NCT03699163)
- Testing
- Breath sample
- Where
- 8 sites in United Kingdom
- Volunteers
- 1,855 people
- Sponsor
- Imperial College London